Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579287 · ClinicalTrials.gov registry record · Phase 2
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
A Phase 2 study of Myopia, Progressive, sponsored by Sunhawk Vision Biotech.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 9
- Study locations
NCT06579287: Active Phase 2 study of Myopia, Progressive, sponsored by Sunhawk Vision Biotech.
NCT06579287 is a Phase 2 study of Myopia, Progressive that is active but no longer recruiting, run by Sunhawk Vision Biotech. The registered enrollment target is 140 participants. The trial reports 9 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06579287, a Phase 2 study of Myopia, Progressive, is active but no longer recruiting, sponsored by Sunhawk Vision Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Conditions Studied
Interventions
- DRUG Atropine
- DRUG SHJ002
Study Locations (9)
Other
- Changhua Christian Hospital - Chang-hua
- Kaohsiung Veterans General Hospital - Kaohsiung City
- Chang Cung Memorial Hospital-Tucheng - New Taipei City
- MacKay Memorial Hospital-Tamsui - New Taipei City
- Chung Shan Medical University Hospital - Taichung
- Cathay General Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
- Tri-Service General Hospital - Taipei
Ohio
- Pacific Center for Advanced Vision Care Tanasbourne Vision Center - Hillsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579287
The ClinicalTrials.gov registry entry for NCT06579287 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunhawk Vision Biotech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 2 interventions - of which Atropine is the first listed.
NCT06579287 reports 9 study locations spanning 2 distinct geographic areas - top geographies include Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT06579287 about?
NCT06579287 is a clinical study titled "A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control". The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
What is the current status of trial NCT06579287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-01-22. Estimated completion is 2026-12.
What conditions does trial NCT06579287 study?
This clinical trial studies the following conditions: Myopia, Progressive.
What interventions are being tested in trial NCT06579287?
The interventions under investigation include: Atropine (DRUG), SHJ002 (DRUG).
Who is sponsoring clinical trial NCT06579287?
This trial is sponsored by Sunhawk Vision Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06579287 being conducted?
This trial has 9 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia, Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.